PURPOSE: To determine if sarpogrelate, a selective 5-HT2A receptor antagonist, is protective against light-induced retinopathy in BALB/c mice. METHODS: BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure. Additionally, a single injection regimen was evaluated by injecting mice with 50 mg/kg sarpogrelate once immediately prior to light exposure. To investigate the potential for additive effects of serotonin receptor agents, a combination therapy consisting of sarpogrelate (15 mg/kg) and 8-OH-DPAT (1 mg/kg) was evaluated with the 5-day treatment regimen. Neuroprotection was characterized by the preservation of retinal thickness and function, measured by spectral-domain optical coherence tomography (SD-OCT) and electroretinography (ERG), respectively. RESULTS: Mice that were light damaged and injected with saline had significantly reduced outer retinal thickness, total retinal thickness, and ERG amplitudes compared with naïve mice. A 5-day administration of 15, 30, or 40 mg/kg of sarpogrelate was able to partially protect retinal morphology and full protection of retinal morphology was achieved with a 50 mg/kg dose. Both 15 and 30 mg/kg doses of sarpogrelate partially preserved retinal function measured by ERG, whereas 40 and 50 mg/kg doses fully preserved retinal function. Additionally, a single administration of 50 mg/kg sarpogrelate was able to fully preserve both retinal morphology and function. Administration of 15 mg/kg of sarpogrelate and 1 mg/kg of 8-OH-DPAT together demonstrated an additive effect and fully preserved retinal morphology. CONCLUSIONS: A 5- or 1-day treatment with 50 mg/kg sarpogrelate can completely protect the retina of BALB/c mice from light-induced retinopathy. Partial protection can be achieved with lower doses starting at 15 mg/kg and protection increases in a dose-dependent manner. Treatment with low doses of sarpogrelate and 8-OH-DPAT elicits an additive effect that results in full protection of retinal morphology.
PURPOSE: To determine if sarpogrelate, a selective 5-HT2A receptor antagonist, is protective against light-induced retinopathy in BALB/c mice. METHODS: BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure. Additionally, a single injection regimen was evaluated by injecting mice with 50 mg/kg sarpogrelate once immediately prior to light exposure. To investigate the potential for additive effects of serotonin receptor agents, a combination therapy consisting of sarpogrelate (15 mg/kg) and 8-OH-DPAT (1 mg/kg) was evaluated with the 5-day treatment regimen. Neuroprotection was characterized by the preservation of retinal thickness and function, measured by spectral-domain optical coherence tomography (SD-OCT) and electroretinography (ERG), respectively. RESULTS:Mice that were light damaged and injected with saline had significantly reduced outer retinal thickness, total retinal thickness, and ERG amplitudes compared with naïve mice. A 5-day administration of 15, 30, or 40 mg/kg of sarpogrelate was able to partially protect retinal morphology and full protection of retinal morphology was achieved with a 50 mg/kg dose. Both 15 and 30 mg/kg doses of sarpogrelate partially preserved retinal function measured by ERG, whereas 40 and 50 mg/kg doses fully preserved retinal function. Additionally, a single administration of 50 mg/kg sarpogrelate was able to fully preserve both retinal morphology and function. Administration of 15 mg/kg of sarpogrelate and 1 mg/kg of 8-OH-DPAT together demonstrated an additive effect and fully preserved retinal morphology. CONCLUSIONS: A 5- or 1-day treatment with 50 mg/kg sarpogrelate can completely protect the retina of BALB/c mice from light-induced retinopathy. Partial protection can be achieved with lower doses starting at 15 mg/kg and protection increases in a dose-dependent manner. Treatment with low doses of sarpogrelate and 8-OH-DPAT elicits an additive effect that results in full protection of retinal morphology.
Authors: Sheldon Rowan; Shuhong Jiang; Tal Korem; Jedrzej Szymanski; Min-Lee Chang; Jason Szelog; Christa Cassalman; Kalavathi Dasuri; Christina McGuire; Ryoji Nagai; Xue-Liang Du; Michael Brownlee; Naila Rabbani; Paul J Thornalley; James D Baleja; Amy A Deik; Kerry A Pierce; Justin M Scott; Clary B Clish; Donald E Smith; Adina Weinberger; Tali Avnit-Sagi; Maya Lotan-Pompan; Eran Segal; Allen Taylor Journal: Proc Natl Acad Sci U S A Date: 2017-05-15 Impact factor: 11.205
Authors: Anna Szilágyi; Barbara Takács; Réka Szekeres; Vera Tarjányi; Mariann Bombicz; Dániel Priksz; Attila Kovács; Béla Juhász; Ede Frecska; Zoltán Szilvássy; Balázs Varga Journal: Biomedicines Date: 2022-04-26
Authors: Marci L DeRamus; Delores A Stacks; Youwen Zhang; Carrie E Huisingh; Gerald McGwin; Steven J Pittler Journal: Sci Rep Date: 2017-02-15 Impact factor: 4.379
Authors: Cristy A Ku; Renee C Ryals; Dan Jiang; Aaron S Coyner; Kyle K Weller; Wrik Sinha; Bryan M Robb; Paul Yang; Mark E Pennesi Journal: Invest Ophthalmol Vis Sci Date: 2018-01-01 Impact factor: 4.799
Authors: Dan Jiang; Renee C Ryals; Samuel J Huang; Kyle K Weller; Hope E Titus; Bryan M Robb; Firas W Saad; Ribal A Salam; Hytham Hammad; Paul Yang; Daniel L Marks; Mark E Pennesi Journal: Invest Ophthalmol Vis Sci Date: 2019-03-01 Impact factor: 4.799
Authors: Diana Marie Battaglia; Maria D Sanchez-Pino; Charles D Nichols; Timothy P Foster Journal: Front Microbiol Date: 2022-03-22 Impact factor: 5.640
Authors: Aaron S Coyner; Renee C Ryals; Cristy A Ku; Cody M Fischer; Rachel C Patel; Shreya Datta; Paul Yang; Yuquan Wen; René Hen; Mark E Pennesi Journal: PLoS One Date: 2016-07-22 Impact factor: 3.240